In consequence, recent in vitro data has shown that, under pressure of the BRAF inhibitor Vemurafenib (PLX4032), human melanoma cells downregulate B7-H6, MICA, ULBP2 and the DNAM-1 ligand CD155, and upregulate MHC class I expression, in order to escape NK-cell mediated tumor cell recognition [30,31]. Here, CD226 is linked to neoplasm.